FAQs

Frequently Asked Questions

How do you incorporate AI into clinical development?

AI is changing clinical development across several fronts, and we put it to work where it genuinely moves a program forward—participant recruitment across registries, regions, and data sources; feasibility modeling; and earlier, sharper safety and data signal detection. In rare and ultra-rare disease, where patient populations are small and every participant matters, these capabilities can meaningfully strengthen a trial’s path forward—but they are only the starting point of multiple collaborations. Patient identification is a key first step. AI can identify where patients may be; engaging them still depends on valuable relationships with clinicians, patient advocacy groups, and the overall community. That human connection is central to how we work, and it is what turns a list of potential study participants into an enrolled, retained, well-supported trial population.

Our philosophy is straightforward: AI identifies candidates and signals; experienced clinical judgment still decides what to act on.

How do you approach patient-centric trial design?

Patient-centricity is a critical design discipline that directly strengthens participant recruitment, enrollment, retention, and overall data quality. We provide support in developing trials around the realities of patients and caregivers: the burden of visits and assessments, travel and access, and what living with a rare disease actually demands and means to them and the community. In rare disease, the patient community is often the most informed voice in the room when developing a study, and designing with that insight from the start may reduce the protocol amendments, recruitment delays, and potential withdrawals from study that significantly impact a study.

How do you engage patient advocacy groups and KOLs?

Deeply, and early. Over more than two decades we have developed lasting relationships with patient advocacy organizations and key opinion leaders across multiple rare diseases—relationships measured in years, not engagements. For sponsors, we provide and support the development of these key collaborations: advocacy groups that inform feasible, patient-centered design and support patient identification and recruitment, and KOLs who strengthen and support the science and lend credibility with their colleagues and regulators. These important relationships are challenging and take time to establish—they are central to how we develop therapies in rare disease.

What makes running rare and ultra-rare disease trials different?

The critical element is patient identification. Patient populations may number in the hundreds (or less) worldwide, so identifying patients is critical and immensely challenging—a fundamentally different approach. In addition, endpoints are often less established, natural history may be incomplete, and regulatory pathways may be less defined. There is little margin for error. We bring highly valued specialization across a plethora of rare and ultra-rare indications, identifying and mitigating these risks and combining scientific rigor with the relationships and judgment that complex rare disease programs require—experience that helps move therapies toward the patients who need them.

How do you work with sponsors?

Synergy provides independent, strategic clinical development consulting services—embedded clinical leadership with founder-level attention on every engagement. Sponsors engage us for direct involvement in multiple areas of clinical development including program strategy, study design, and support in key relationships that move a trial forward. We collaborate with you and your team, complementing your existing CRO and vendor partners. We adapt to the needs of each program, providing flexible, responsive support that scales with your priorities at every stage of development.

Scroll to Top